General Internal Medicine

Supportive Care

Questions discussed in this category

Should GLP-1 agonists be held during chemotherapy?

3 Answers available

What are your top takeaways in Hematologic Malignancies from ASH 2024?

12 Answers available

Can defibrotide be given safely for VOD in patients with refractory thrombocytopenia to platelet transfusions?

1 Answer available

How can oncologists be more collaborative with palliative care physicians?

How can these interactions be improved?

1 Answer available

Would you consider TPO mimetics for chemotherapy induced thrombocytopenia that persists despite dose reductions?

1 Answer available

How do you approach IVIG replacement for pediatric patients with low IgG during treatment for hematologic malignancies?

Do you routinely check IgG levels during therapy, if not indicated by a study protocol?

1 Answer available

How do you manage patients with chemotherapy-induced paronychia?

1 Answer available

How do you approach conversations regarding discontinuation of transfusions in patients with advanced hematologic malignancies who are otherwise appropriate for hospice?

Are there other supportive care interventions that would otherwise be covered by hospice?

1 Answer available

What is your preferred treatment to ameliorate bone pain from G-CSF?

1 Answer available

Papers discussed in this category

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009-10

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Journal of pediatric hematology/oncology, 2019-08

Impact of IgG Monitoring and IVIG Supplementation on the Frequency of Febrile Illnesses in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Maintenance Chemotherapy.

Journal of palliative medicine, 2012-11

Conceptual models for integrating palliative care at cancer centers.

Nature reviews. Clinical oncology, 2016-03

Integrating palliative care into the trajectory of cancer care.

Blood, 2016-03-31

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.

Bone marrow transplantation, 2016-07

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.

Bone marrow transplantation, 2018-02

Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.

British journal of haematology, 2020 Mar 04

Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation.

Blood advances, 2022 Jan 11

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2020 Jan-Dec

A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting.

Bone marrow transplantation, 2022 Dec 23

Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study.

Cancer, 2023 Jun 24

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.

The New England journal of medicine, 2024 Jun 03

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

BMJ open, 2024 Oct 09

Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study.

JAMA network open, 2024 Jul 01

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.

Related Topics in General Internal Medicine